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doi:10.1016/j.ejvs.2009.01.026Abstract Although there is level I evidence supporting the role of carotid endarterectomy
(CEA) in patients with asymptomatic disease, opinion remains polarised regarding what consti-
tutes optimal management, especially as carotid artery stenting (CAS) has emerged as a less
invasive alternative. Reasons for this lack of consensus amongst surgeons, interventionists,
neurologists and stroke physicians include our continued inability to identify ‘high risk for
stroke’ patients in whom to target costly therapies. For example, recent data from the USA
suggest that up to $21 billion is being spent each year on ultimately ‘unnecessary’ interven-
tions. Second, is growing evidence that improvements in what now constitutes modern ‘best
medical therapy’ has significantly reduced the risk of stroke compared to that observed in
ACAS and ACST. If true, this will compromise risk:benefit analyses used in national and inter-
national guidelines.
At a time when evidence suggests that up to 94% of interventions may not benefit the
patient, the authors urge that at least one of the randomised trials comparing CEA with CAS
in asymptomatic patients includes an adequately powered third limb for BMT. Timely invest-
ment now could optimise patient care and resource utilisation for all of us in the future.
ª 2009 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.of Vascular Surgery, Clinical
mary, Leicester LE2 7LX, UK.
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.nhs.uk (A.R. Naylor).
ty for Vascular Surgery. Publishe‘‘All professions are a conspiracy against the laity’’
George Bernard Shaw (1856e1950)
Two randomised controlled trials (RCTs), the Asymptomatic
Carotid Atherosclerosis Study (ACAS)1 and the Asymptom-
atic Carotid Surgery Trial (ACST)2, concluded that carotidd by Elsevier Ltd. All rights reserved.
Table 1 Five year risks of the main outcomes from ACAS and ACST, including the operative risk
ACAS ACST
BMT CEA ARR BMT CEA ARR
Any stroke 17.5% 12.4% 5.1% 11.8% 6.4% 5.4%
No of ‘any strokes’ prevented
per 1000 CEAs at 5 years
51 54
Any major stroke 9.1% 6.4% 2.7% 6.1% 3.5% 2.6%
No of ‘major strokes’ prevented
per 1000 CEAs at 5 years
27 26
Ipsilateral stroke 11.0% 5.1% 5.9% 5.1%* 4.4%* 1.1%
No of ipsilateral strokes prevented
per 1000 CEAs at 5 years
59
Major ipsilateral stroke 6.0% 3.4% 2.6% n/a n/a n/a
BMTZ best medical therapy, CEAZ carotid endarterectomy, * data derived from presentations about the 10 year ACST data. In the CEA
group it includes a 2.8% operative risk, n/aZ no data available, ARRZ absolute risk reduction at 5 years.
626 A.R. Naylor et al.endarterectomy (CEA) conferred a 50% relative risk reduc-
tion in the 5 year risk of ‘stroke’ from approximately 12%
down to 6% (Table 1). However, despite level I (Grade A)
evidence supporting intervention, the management of
patients with asymptomatic carotid disease continues to
polarise opinion around the world.
It is inevitable, of course, that practice will reflect polit-
ical/financial priorities within health systems, but the
magnitude of variation seems remarkable, especially as it is
based upon an interpretation of the same published data.
The Iberian Medical Tourism Network, for example, suggests
that the indications for carotid artery stenting (CAS) in
asymptomatic patients are ‘‘essentially the same as for
standard open CEA’’ and its website will quote for both
interventions.3 In 2005, 135,701 carotid revascularisations
were performed in the USA. Of these, 122,986 (92%) were in
asymptomatic patients4; almost one tenth being by CAS. By
contrast, only 20% of reconstructions in the UK are performed
in asymptomatic patients (very few by CAS),5 while the
Belgian Government will reimburse surgeons for performing
CEA in asymptomatic patients but not following CAS.6
Enthusiasm for intervening is highest amongst those
surgeons, radiologists and cardiologists who promote their
procedures and lowest amongst neurologists and stroke
physicians. As early as 1996, Barnett questioned whether
the available evidence justified the huge increase in CEA
numbers following publication of ACAS.7 In 1997,Table 2 Global variation in opinion on how a 67 year old
non-smoking male with hypertension, hyperlipidaemia and
a 70e80% asymptomatic stenosis should be managed (*)
Continent Respondents BMT (%) CAS (%) CEA (%)
North America nZ 2227 47 17 36
Europe nZ 1161 48 19 33
South America nZ 545 49 25 26
Asia & Russia nZ 425 56 24 20
Australia & Oceania nZ 118 56 14 30
Africa nZ 39 44 31 26
(*) based on data from an on-line vote run by the New England
Journal of Medicine.11 BMTZ best medical therapy,
CASZ carotid artery stenting, CEAZ carotid endarterectomy.a consortium of Canadian stroke neurologists campaigned
against screening and intervention in asymptomatic
patients.8 By 2003, some called for the RCTs to be
repeated,9 while by 2008 some even felt that improvements
in what constituted ‘best medical therapy’ meant that no-
one need undergo any intervention at all.10 The lack of
consensus was illustrated by a 2008 poll undertaken by the
New England Journal of Medicine.11 A case scenario was
presented (67 year old non-smoking male with hyperten-
sion, hyperlipidaemia and a 70e80% NASCET derived
asymptomatic carotid stenosis) and three experts advised
on how he should be managed. Having considered the
‘expert’s’ advice, almost 5000 readers then voted their own
recommendations. Interestingly, almost half (49%) said they
would treat the patient medically, 32% recommended CEA,
while 19% said they would perform CAS. Table 2 shows that
the most frequent response from every continent (including
North America) was a recommendation for conservative
management.
So why, despite two large RCTs, is opinion still so polar-
ised? The main reasons include: (i) our continued inability to
identify ‘high risk for stroke’ patients in whom to target
costly (and potentially risky) interventions; and (ii) a belief
that improvements in what now constitutes ‘best medical
therapy’ may have significantly reduced the risk of stroke
compared to that observed in ACAS and ACST. A third and
more controversial reason (to which George Bernard Shaw
would undoubtedly subscribe) is the fact that intervening in
asymptomatic patients remains a major source of income to
surgeons and interventionists around the world.
Following publication of the symptomatic trials, it was
possible to identify subgroups of patients who were at
increased risk of suffering a stroke on medical therapy but
not at significantly increased operative risk.12 The impor-
tant factors included; male gender, increasing age (espe-
cially >75 years), hemispheric vs ocular symptoms,
increasing medical co-morbidity, very recent symptoms
(especially the first 2 weeks), irregular vs smooth plaques,
increasing degrees of stenosis (but not subocclusion),
contralateral occlusion, tandem intracranial disease and
a failure to recruit intracranial collaterals. By contrast,
other than ACST observing that CEA conferred no significant
benefit in patients aged >75 years (a finding currently
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conclusions regarding who might benefit most (and least)
from intervention for asymptomatic stenosis were
forthcoming.
The need to target CEA/CAS towards high risk (for
stroke) asymptomatic patients cannot be overstated. Even
if it were possible to identify and then operate upon every
single patient with an asymptomatic 60e99% stenosis in the
whole population, fewer than 5% of all strokes in the pop-
ulation would be prevented.13,14 The cost of screening and
intervention would, however, be enormous and would
undoubtedly draw funds from other more cost-effective
preventive strategies. The following section will deal with
current practice in the USA (largely because they have
published most data), but there are important messages for
many other health systems.
The Centres for Medicare and Medicaid Services predict
that US Healthcare spending will nearly double to $4.3
trillion by 2017, i.e. about 20% of GDP.15 Commenting upon
these predictions,15 Professor Brian Rubin observed that
‘‘publically funded healthcare in the USA was about to be
hit by the ‘perfect storm’ and that difficult decisions lay
ahead, hopefully driven by evidence based studies as to
which therapies offer an adequate return on investment.’’
So where does the management of asymptomatic carotid
disease feature in any discussions regarding an ‘adequate
return on investment’?
Using the US statistics,4 122,986 revascularisations in
asymptomatic patients were performed in 2005 (91% CEA,
9% CAS). Because McPhee published an estimate of total
hospital costs in his paper, it is now possible to model the
financial implications (total hospital costs) against the late
benefits (strokes prevented) for this cohort of patients.
Using the ACAS data summarised in Table 1, 59 ipsilateral
strokes will be prevented at 5 years by performing 1000
CEAs assuming a 2.3% procedural risk. The parallel figure for
‘any strokes’ prevented is 51. If these values are now
applied to the 2005 national data, this means that 7256
ipsilateral strokes would be prevented at 5 years
(59  122.986). Conversely, this means that 115,730
patients (94%) underwent an unnecessary procedure. Using
the US definition of a billion, this equates to a $21 billionFigure 1 Annual rates of ipsilateral stroke in patients with an a
baseline. The authors acknowledge that many of the studies werecost to the US Health Services for ‘unnecessary interven-
tions’ in that calendar year. The cost incurred for pre-
venting one ipsilateral stroke at 5 years would therefore be
$319,551 and the parallel figure for preventing one ‘any
stroke’ at 5 years would be $369,685.
However, these data were modelled upon the proce-
dural risks observed in ACAS (2.3%). If 30-day risk data from
the 2004 US Multistate CEA audit were used instead, the
benefits and costs change considerably.16 In this audit, the
procedural risk of stroke and death in asymptomatic
patients was 3.8%. If this is a truer reflection of ‘real world’
practice, the number of ipsilateral strokes prevented per
1000 CEAs at 5 years falls to 44, the total number of strokes
prevented in the cohort of 122,986 patients falls to 5411
(i.e. 117,575 would undergo an unnecessary procedure),
leading to an average total hospital cost of $428,510 per
stroke prevented.
So who might benefit most (and least) from prophylactic
intervention? Unfortunately, neither ACAS nor ACST have
really been able to help. Contrary to assumptions before
the trials commenced, neither has demonstrated any rela-
tionship between stenosis severity and late stroke risk (i.e.
the total opposite of the symptomatic trials). Despite this,
some advocates of intervention still feel that it is almost
unethical not to intervene in patients with 80e99%
stenoses, as opposed to 60e79%.17 This conclusion is not,
however, supported by any other natural history study.
Figure 1 details the annual risk of ipsilateral stroke in 26
natural history studies relative to the degree of stenosis
measured when the patient entered the study.18e43 Note
that across a wide range of stenoses (including 80e99%),
the annual risk of stroke rarely exceeded 3% and none
exceeded 4%. One exception (not included in this figure) is
a subgroup analysis in the ACSRS study which showed that
patients with a 90e99% stenosis plus a history of contra-
lateral TIA plus renal impairment faced a 6.5% annual risk
of stroke.47 All of the remaining patients in the 90e99%
stenosis category incurred a 1% annual ipsilateral stroke
risk. In reality the number of patients likely to fulfil all
three of these high risk caveats is inconsequential.
More fundamentally, we have still not even determined
whether women gain significant benefit from prophylacticsymptomatic carotid stenosis stratified for stenosis severity at
sourced from Abbott,44 Touze45 and Rijbroek.46.
Table 3 Temporal changes in the 5 year risk of ‘any’
stroke and ‘ipsilateral’ stroke in ACAS and ACST
Trial Years Year
published
‘Any’
stroke (%)
‘Ipsilateral’
stroke (%)
ACAS 1e5 1995 17.5 11.0
ACST 1e5 2004 11.8 5.3a
ACST 6e10 2009 7.2a 3.6a
a Z derived from oral presentations of the 10 year ACST
data.
628 A.R. Naylor et al.CEA (or CAS). In ACAS, CEA conferred no benefit in
females,1 even when the operative risk was later
excluded.48 ACST claimed that women gained significant
benefit at 5 years, but this only held true if the operative
risk was excluded.49 When the operative risk was included,
all significant benefit ceased.49 In the 2005 Cochrane
Review,50 males gained a highly significant 50% reduction in
the risk of late stroke (OR 0.50, 95% CI 0.36e0.67), while
CEA conferred no benefit in women (OR 1.0, 95% CI
0.6e1.7). The likely reason for the apparent lack of benefit
in women is a combination of there being a slightly higher
operative risk in women (4.0% vs 2.4% in ACST, 3.6% vs 1.7%
in ACAS) in conjunction with a lower 5 year risk of stroke on
medical therapy compared with men (8.7% vs 12.1% in
ACAS; 7.5% vs 10.6% in ACST)). Accordingly, if one were to
use ACAS and ACST data to predict who might fall into
a category of being considered ‘higher risk for stroke’ on
best medical therapy, they would have to be males under
the age of 75 years.
The second important reason underlying uncertainty
about how best to manage patients with asymptomatic
carotid disease is a growing belief that improvements in
what now constitutes ‘best medical therapy’ may have
reduced the natural history risk of stroke to levels below
that observed in ACAS and ACST. This is a very important
issue to be resolved as if the annual rate of fatal/major
stroke falls below 1.1%, no benefit will ever accrue to any
patient from CEA.51
In ACAS, ‘best medical therapy’ included advice to stop
smoking, control of blood pressure and aspirin therapy.
Unfortunately, ACAS did not publish data regarding
changing trends in therapy or drug compliance, but rela-
tively few will have received statins. By contrast, ACST has
published considerable data on changes in medical therapy
during the 10 years that the trial recruited.2 The majority
(90%) received antiplatelet therapy throughout the study,
while 70% were on antihypertensive therapy when the trial
concluded in 2003. The most important change in practice
was a progressive increase in the proportion of patients
receiving statin therapy from 17% (1993e1996) to 58% by
2000e2003. By the end of 2003, 70% were taking statins and
by 2008, the figure was over 90%. It is, however, importantFigure 2 Annual rates of ipsilateral and ‘any’ stroke in patient
publication. The authors acknowledge that many of these studiesto note that by the midpoint of the trials duration (1997),
fewer than 40% of ACST patients were taking statins. More
importantly, the doses of statins used in the first 5 years of
ACST would have been much lower than are currently rec-
ommended. Simvastatin (10 mg daily) was the most
commonly used dose in the 1990s. Second, is a potential
anomaly regarding the prescription of statins in women.
Until the British Heart Protection Study published in 2002,52
usual practice in the UK was to only prescribe statins to
asymptomatic patients if they were male, had an elevated
cholesterol level, were under the age of 75 years and had
ischaemic heart disease. Accordingly, prior to 2002,
a significant proportion of female patients were probably
not receiving statin therapy.
However, increasing statin use is only part of what
constitutes the modern concept of ‘best medical therapy.’
Any future RCT (including a medical limb) would probably
recommend even more aggressive blood pressure control
using multiple therapeutic agents, especially in type II
diabetics. There would be obligatory statin therapy at
a relatively high dose, dual antiplatelet therapy (probably
aspirin and dipyridamole as recommended by the American
College of Chest Physicians), low dose ACE inhibition (now
recommended by the AHA), more aggressive lifestyle
modification advice (smoking cessation, exercise, diet) and
the avoidance of hormone replacement therapy in women.
No RCT has ever compared this modern concept of ‘best
medical therapy’ with intervention in patients with
asymptomatic carotid stenosis.s with an asymptomatic 50e99% stenosis stratified by date of
were sourced from Abbott.44.
Who Benefits Most from Intervention for Asymptomatic Carotid Stenosis? 629What evidence is there that improvements in medical
therapy are reducing the annual risk of stroke? Table 1 is
a summary of the principal findings from ACAS and ACST,
while Table 3 specifically focuses on temporal changes in
the 5 year risks of ‘any’ and ‘ipsilateral’ stroke in these two
trials. Note that between 1995 (when ACAS published) and
2004 (when ACST first published), the 5 year risk of ‘any
stroke’ had declined from 17.5% in ACAS to 11.8% in ACST.
This represents a 33% relative risk reduction during the
9 year period. There were also proportional reductions in:
(i) the 5 year risk of any major stroke (down 33% from 9.1%
in ACAS to 6.1% in ACST (Table 1)); and in (ii) ipsilateralTable 4 Demographics and methodology of the randomised tria
Methodology ACT 1 ACST II
Type of triala Non-inferiority Equivalence
Multi-centre Yes Yes
Recruiting country North America Worldwide
Treatment optionsb CAS vs CEA CAS vs CEA
Funding source Abbott Vascular NHS R þ D and HT
Number intended
to be in triale
1858 5000
Randomisation ratiosf CAS 3: CEA 1 CAS 1: CEA 1
Randomisation started? Yes Yes
Track record
of participantsg
Yes Yes
Proctoring/mentoring
allowedh
No No
Stenosis rangei ‘Severe’ ‘Severe’
Stenosis measurement
methodj
NASCET NASCET & ECST
Stent used
in study
Xact Rapid
Exchange
CE approvedk
Cerebral protection
device
obligatory Optional
Type Emboshield CE approvedk
Dual antiplatelet
therapy
Yes Yes
Endpoints 30-day
death/stroke/MI
30-day
death/stroke/MI
>30-day to 1 year
ipsilateral
stroke neurocognitive
decline
5 year stroke
(any/disabling)
Contact details www.act1trial.com acst@sgul.ac.uk
a Non-inferiority, equivalence, superiority.
b Carotid angioplasty (CAS), carotid endarterectomy (CEA), best me
c National Health Service Research Health Technology Assessment p
e Number of patients that power calculation deems necessary for tr
f Ratio of CAS to CEA in trial.
g Is a track record review undertaken in order to select trial partici
h Does your trial allow for less experienced CAS practitioners to ra
tioners before being allowed to perform CAS independently within th
i Range of stenoses being randomised.
j Stenosis measurement method; i.e. NASCET, ECST.
k FDAZ Food and Drug Administration approved, CE mark indicates
Directives.stroke (down 52% from 11.0% in ACAS to about 5.3% in ACST
(Table 3)). Interestingly, there is now evidence of a still
further decline in the 5 year risk of stroke in the 10 year
data currently being presented by ACST to national meet-
ings. Table 3 shows that in the second 5 year period of ACST
(i.e. years 6e10), the 5 year risk of ‘any’ stroke was now
7.2% (i.e. down 39% on the 11.8% reported in 2004), while
the 5 year risk of ipsilateral stroke in the second 5 year
period had fallen to 3.6% (down 32% from 5.3% in 2004).
Further evidence supporting a declining stroke risk (with
time) comes from Figure 2 which shows the annual rate of
‘ipsilateral’ and ‘any’ stroke in 16 studies involving patientsls in asymptomatic patients
TACIT SPACE II
Superiority Superiority CEA/CAS vs BMT
non-inferiority CAS vs CEA
Yes Yes
North America & Europe Germany, Austria, Switzerland
CAS vs CEA vs BMT CAS vs CEA vs BMT
Ac Not yet determined BMBF/DFG
2500 3640
CEA 1: CAS 1: BMT 1 CEA 1550: CAS 1550: BMT 540
No No
Yes Yes
No No
50% 50% NASCET
NASCET NASCET & ECST
FDA/CE approvedk CE approvedk and approved
by the CAS quality committee
Obligatory optional
FDA/CE approvedk CE approvedk and approved
by the CAS quality committee
Yes Yes
30-day death/stroke/MI Safety: 30-day death
or any stroke
5 year stroke rate Efficacy: 30-day any stroke
or death plus 5 year ipsilateral
ischemic stroke
TACIT@SIRFoundation.org Neurologie@med.uni-
heidelberg.de
dical therapy (BMT).
rogramme.
ial completion.
pants.
ndomise patients but be proctored by more experienced practi-
e trial.
that the product meets the requirements of all relevant European
630 A.R. Naylor et al.with 50e99% asymptomatic carotid stenoses published
since 1985.1,2,18,21,22,25,26,28,32,34,37,39,40,44,53 Once again,
there is evidence of a sustained decline in the annual rate
of stroke (ipsilateral and any) over the last two decades and
which has continued since the publication of ACST in 2004.
The most recent study (SMART) reported annual rates of
‘any stroke’ and ipsilateral stroke of <1%.32
We, therefore, believe that there is still considerable
uncertainty about how best to manage patients with
asymptomatic carotid disease. In our opinion, consensus
will only be achieved if one of the trials evaluating CEA with
CAS in asymptomatic patients includes an adequately
powered third limb for medically treated patients.
However, reliance only upon stenosis severity for patient
selection may no longer be appropriate. More sophisticated
methods are required in order to identify the relatively
small subset of patients at highest risk of suffering a late
stroke, in whom intervention is still likely to be more
effective than best medical treatment alone. For example,
Spence has shown that the annual risk of stroke was only 1%
in patients with an asymptomatic 60e99% stenosis and no
baseline evidence of embolisation on transcranial Doppler
(TCD),54 but was 15% in patients with TCD evidence of
embolisation. Larger studies are nearing completion and
will greatly inform the debate.55 Similarly, something as
simple as performing a CT scan (identifying pre-existing
infarction) or looking at the patency of the circle of Willis
may impart valuable information regarding long term
prognosis. In a recent subgroup analysis from the ACSRS,
patients with a 60e99% stenosis and an ipsilateral infarct on
CT scan incurred a 3.6% annual rate of stroke over the
ensuing 8 years as compared with only 1.0% in patients with
similar stenoses but no infarction.56 Similarly, patients
randomised into a medical limb could undergo serial
biomarker evaluation and/or novel imaging strategies
including evaluation of intraplaque haemorrhage on MR57 or
image normalised Grey Scale Median measurement using
ultrasound.58 ACST and ACAS cannot be faulted for not
having used these new techniques when they were
recruiting, but we now need more discriminating investi-
gative strategies for the future. Only then might it become
possible to develop a predictive scoring system to enable
the targeting of therapy to the most vulnerable patients.
However, unless one of the planned RCTs includes an
adequately powered third limb, the moment will be lost.
The inevitable consequence will be that in 5e10 years time
when the trials begin to report, we will continue to spend
huge amounts of money on unnecessary treatments and we
will have to make comparisons with natural history data
derived from the medical limbs of trials started two or three
decades earlier. Table 4 summarises the four trials intend-
ing to make a randomised comparison between CAS and CEA
in asymptomatic patients. CREST (not mentioned in Table 4,
but recently completed) included about 1000 asymptomatic
patients and will report preliminary data later this year.
They did not include a medical limb. ACT-1 has already
started to recruit. It does not have a medical limb and only
allows ‘elite’ interventionists and surgeons to participate. It
is inevitable that there will be questions about the gen-
eralisability of its findings. ACST II has just started recruiting
and plans to randomise 5000 patients. The authors accept
that it may be difficult to change trial methodology at thislate stage, but it is likely that the lack of a medical arm will
be cited at a later date as being a major limitation. SPACE II
is about to start in Germany, Austria and Switzerland. It is
unique in that it has secured funding for a third medical
limb, but it only plans to randomise 500 patients to medical
treatment only. Unfortunately clinicians from outside these
three countries cannot randomise patients (could that
change?). Moreover, given past experience, it is likely that
500 patients will not be large enough to identify a clinically
relevant high risk subgroup and there is no guidance (as yet)
as to whether SPACE II plans to measure plasma biomarkers
or use novel imaging strategies in their medically managed
patients.
The only other study is TACIT, which is the only trial
planning to recruit patients into three large limbs, but it is
struggling to secure funding. In addition to traditional
endpoints, TACIT plans to evaluate neurocognitive changes,
quality of life issues and carotid plaque characteristics. If it
were funded, it would allow clinicians from around the
world to randomise patients into either ACST II, TACIT or
SPACE II according to patient preference and/or physician
equipoise. At present, however, TACIT still needs to secure
$60 million funding over a 5 year period, but could begin if
$20 million were committed over a 3 year period (John
Rundback, personal communication). Although these seem
large sums of money, given that about $21 billion is
currently being spent each year on unnecessary interven-
tions in asymptomatic patients in the USA, it does seem
disappointing that funding has not been forthcoming. Now
would seem an ideal opportunity for health systems around
the world to contribute relatively little towards a trial that
could end up saving a lot of resources for all of us in the
future.
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